Gabapentin vs Pregabalin for Neuropathic Pain: Key Differences

Gabapentin and pregabalin are both alpha-2-delta calcium channel ligands, and both work for neuropathic pain — but they are not identical. Pregabalin has more predictable pharmacokinetics, faster dose titration, and two FDA approvals for neuropathic pain (diabetic neuropathy and postherpetic neuralgia) plus one for fibromyalgia. Gabapentin is older, off-patent and far cheaper, and has a longer track record for postherpetic neuralgia specifically. Neither has been shown clearly superior to the other for most neuropathic pain conditions — the choice often comes down to cost, titration schedule, renal function, and individual tolerability.

This explainer draws on peer-reviewed research from three neurologists listed in the Convene directory: Michael Rowbotham, M.D., at UCSF, who authored the landmark 1998 gabapentin randomized controlled trial for postherpetic neuralgia and co-led the 2015 NeuPSIG systematic review; Eva Feldman, M.D., Ph.D., at Michigan Medicine, who co-authored the American Academy of Neurology evidence-based guideline on painful diabetic neuropathy; and Charles Argoff, M.D., at Albany Medical Center, whose work on quality-of-life in diabetic neuropathic pain and refractory treatment options has helped define when first-line drugs are not enough.

How both drugs work

Gabapentin and pregabalin share the same molecular target: the alpha-2-delta subunit of voltage-gated calcium channels in the nervous system. By binding to this subunit, both drugs reduce the release of excitatory neurotransmitters — including glutamate, norepinephrine, and substance P — from pain-transmitting neurons. The result is a dampening of abnormal electrical activity in the peripheral and central nervous system that drives neuropathic pain.

One thing they do not do is block sodium channels. Traditional anticonvulsants like carbamazepine and phenytoin work through sodium channels. Gabapentinoids take a different route, which is partly why their side-effect profiles differ from older seizure drugs.

The key pharmacokinetic difference between the two lies in how the gut absorbs them. Gabapentin is absorbed by a saturable transport system in the small intestine. As the dose goes up, a smaller percentage of the drug actually enters the bloodstream — absorption is non-linear. Higher doses do not reliably produce proportionally higher blood levels. Pregabalin, despite being structurally related, uses the same transporter more efficiently. Its absorption is linear and predictable across the therapeutic dose range. That means the blood level you get is proportional to the dose you take, titration is more straightforward, and the twice-daily dosing schedule used in most trials is sufficient for most patients.

What the evidence shows

The 1998 randomized controlled trial published in JAMA established gabapentin as effective for postherpetic neuralgia in a rigorous placebo-controlled design [2]. Patients who received gabapentin had significantly lower pain scores, better sleep, and better mood. That trial — with Rowbotham as a lead author — gave physicians the first high-quality evidence that a non-opioid, non-antidepressant could meaningfully reduce one of the most treatment-resistant neuropathic pain conditions.

Pregabalin followed with its own trial evidence. A 2005 randomized, double-blind, placebo-controlled trial published in Arthritis & Rheumatism showed that pregabalin reduced pain and improved patient function in fibromyalgia syndrome [4]. Along with earlier trials in postherpetic neuralgia and diabetic neuropathy, this body of evidence supported FDA approvals for multiple conditions.

The most comprehensive synthesis came in 2015, when the NeuPSIG (Special Interest Group on Neuropathic Pain) published a systematic review and meta-analysis in The Lancet Neurology covering 229 randomized trials and more than 17,000 patients [1]. Both gabapentin and pregabalin showed efficacy for neuropathic pain, with a number needed to treat (NNT) of roughly 6 to 8 for 50% pain reduction. Neither drug was proven superior to the other in head-to-head trials. Crucially, the review also found that both drugs performed better than expected from earlier trials when more rigorous methods were applied — but also that effect sizes are moderate, not dramatic, for most patients.

The 2018 IASP classification of chronic pain for ICD-11 provides the nosological framework that informs how physicians categorize neuropathic pain conditions and design treatment trials [3]. That classification, published in the journal Pain, distinguishes neuropathic pain (pain arising from lesion or disease of the somatosensory nervous system) from other chronic pain types — a distinction that matters because gabapentinoids are not broadly effective for all chronic pain, only for conditions with a clear neuropathic component.

At a glance

FDA approvals and common uses

Gabapentin carries FDA approval for postherpetic neuralgia in adults and as add-on therapy for partial seizures. Despite having only one pain-related approval, it is one of the most widely prescribed drugs in the United States, with a large portion of prescriptions written off-label for diabetic neuropathy, sciatica, chemotherapy-induced peripheral neuropathy, and other neuropathic conditions.

Pregabalin holds FDA approvals for postherpetic neuralgia, diabetic peripheral neuropathy, fibromyalgia, generalized anxiety disorder, and as adjunctive therapy for partial-onset seizures. That broader approval list reflects a more systematic clinical trial program — not necessarily superior efficacy. Pregabalin is also classified as a Schedule V controlled substance because of evidence suggesting misuse potential, particularly in patients with a history of substance use disorders. Gabapentin is not federally scheduled, though several states have added it to their controlled substance schedules based on similar concerns.

The AAN evidence-based guideline on treatment of painful diabetic neuropathy, co-authored by Eva Feldman and published in Neurology, evaluated both drugs against the full body of trial evidence available at the time [5]. Both gabapentin and pregabalin received Level B recommendations (probably effective), placing them on equal footing for that indication in terms of the guideline hierarchy.

Side effects and tolerability

The most common side effects for both drugs are dizziness and somnolence. These affect a substantial fraction of patients — roughly 20 to 30% in clinical trials — and are dose-dependent. Peripheral edema (swelling in the feet and lower legs) and weight gain occur with both drugs and can be problematic for patients with cardiovascular conditions or those already dealing with obesity.

One practical difference is onset: pregabalin reaches therapeutic doses faster, which means its side effects appear sooner in the titration process. Some patients find this easier to manage because they know quickly whether they will tolerate the drug. For gabapentin, the slower three-times-daily titration can mean several weeks before the full side-effect profile is apparent.

Renal function matters for both drugs. Gabapentin and pregabalin are both renally cleared, and dose adjustments are required when kidney function is impaired. Severe renal impairment or dialysis dependence requires significant dose reduction for both.

Abrupt discontinuation of either drug can cause withdrawal symptoms including anxiety, insomnia, nausea, and in some cases seizures in patients who have been taking high doses for a long time. Both should be tapered rather than stopped suddenly.

When gabapentinoids are not enough

A meaningful proportion of patients with neuropathic pain remain inadequately treated on gabapentinoids alone. Charles Argoff and colleagues examined this problem directly in a 2006 paper published in Mayo Clinic Proceedings focusing on diabetic peripheral neuropathic pain, documenting the quality-of-life burden that persists even with pharmacotherapy [6]. Many patients on guideline-recommended doses still report pain that interferes significantly with sleep, function, and mood.

For refractory cases, several escalation options exist. Combining a gabapentinoid with duloxetine (an SNRI that also carries a Level B recommendation for diabetic neuropathy) is a common approach and has more trial support than combining two gabapentinoids. Tricyclic antidepressants remain an option for some patients. For severe, treatment-refractory pain, interventional approaches are increasingly supported by evidence. A 2021 randomized controlled trial published in JAMA Neurology evaluated high-frequency (10 kHz) spinal cord stimulation in patients with painful diabetic neuropathy who had failed or were intolerant of medications — and found significant, sustained pain reduction compared to conventional medical management [7]. This is not a first-line option, but it is a legitimate option for patients who have not responded to multiple medication trials.

What the AAN guideline says

The 2011 AAN evidence-based guideline on treatment of painful diabetic neuropathy, co-authored by Eva Feldman, evaluates first- and second-line options across the drug classes used for this condition [5]. Both pregabalin and gabapentin receive Level B recommendations, meaning the evidence probably supports their use — the same tier as duloxetine and tapentadol.

In practice, many pain specialists and neurologists use pregabalin or duloxetine as the first choice based on the combination of evidence strength, dosing convenience, and tolerability profile. Gabapentin remains a reasonable first choice, particularly when cost is a primary concern — it has been generic for many years and carries significantly lower out-of-pocket cost than branded pregabalin, though generic pregabalin has closed much of that gap since 2019.

The guideline does not support one gabapentinoid over the other on efficacy grounds. The practical decision often depends on the individual patient: how quickly they need to reach therapeutic doses, whether they have insurance coverage, whether they have renal impairment requiring careful dosing, and whether their pain condition has a formal FDA indication for one drug but not the other.

Questions to ask your neurologist

• Which specific neuropathic pain condition do I have, and does it have an FDA indication for gabapentin, pregabalin, or both?
• Given my kidney function and other medications, which drug is safer for me to start?
• How quickly do I need to titrate, and how will we know what an adequate dose looks like?
• If I have tried one gabapentinoid without adequate relief, should I try the other, or is it more likely to help to try a different drug class instead?
• At what point in my treatment course should I be referred to a pain specialist or consider interventional options?

The bottom line

Gabapentin and pregabalin work by the same mechanism and have similar overall efficacy for most neuropathic pain conditions — no head-to-head trial has clearly shown one to be more effective than the other. Pregabalin offers faster titration, more predictable pharmacokinetics, and a broader set of FDA approvals; gabapentin is cheaper and has a longer track record for postherpetic neuralgia. For patients who do not get adequate relief from either drug alone, evidence-based escalation options exist, including combination pharmacotherapy and, for truly refractory cases, interventional approaches like high-frequency spinal cord stimulation.